Evidence map›Paper›PMID 32628741›Full record

ArticlePloS one2020

Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control.

Laia Cirera, Beatriz Galatas, Sergi Alonso, Krijn Paaijmans, Miler Mamuquele, Helena Martí-Soler, Caterina Guinovart, Humberto Munguambe, Fabião Luis, Hoticha Nhantumbo and 9 more

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Mass Drug Administration: Contextual Factor Considerations.The American journal of tropical medicine and hygiene · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Laia CireraISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0001-5157-2963
Beatriz GalatasISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Sergi AlonsoCentre for Primary Care and Public Health, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom.
Krijn PaaijmansISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Miler MamuqueleCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Helena Martí-SolerISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Caterina GuinovartISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Humberto MunguambeCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Fabião LuisCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Hoticha NhantumboCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Júlia MontañàISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Quique BassatISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Baltazar CandrinhoNational Malaria Control Program, Ministry of Health, Maputo, Mozambique.
Regina RabinovichISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Eusebio MaceteCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Pedro AideCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Pedro AlonsoISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.
Francisco SaúteCentro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique.
Elisa SicuriISGlobal, Hospital Clínic -Universitat de Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs new combinations of interventions aiming at interrupting malaria transmission are under evaluation, understanding the associated economic costs and benefits is critical for decision-making. This study assessed the economic cost and cost-effectiveness of the Magude project, a malaria elimination initiative implemented in a district in southern Mozambique (i.e. Magude) between August 2015-June 2018. This project piloted a combination of two mass drug administration (MDA) rounds per year for two consecutive years, annual rounds of universal indoor residual spraying (IRS) and a strengthened surveillance and response system on the back of universal long-lasting insecticide treated net (LLIN) coverage and routine case management implemented by the National Malaria Control Program (NMCP). Although local transmission was not interrupted, the project achieved large reductions in the burden of malaria in the target district.

methodsWe collected weekly economic data, estimated costs from the project implementer perspective and assessed the incremental cost-effectiveness ratio (ICER) associated with the Magude project as compared to routine malaria control activities, the counterfactual. We estimated disability-adjusted life years (DALYs) for malaria cases and deaths and assessed the variation of the ICER over time to capture the marginal costs and effectiveness associated with subsequent phases of project implementation. We used deterministic and probabilistic sensitivity analyses to account for uncertainty and built an alternative scenario by assuming the implementation of the interventions from a governmental perspective. Economic costs are provided in constant US$2015.

resultsAfter three years, the Magude project averted a total of 3,171 DALYs at an incremental cost of $2.89 million and an average yearly cost of $20.7 per targeted person. At an average cost of $19.4 per person treated per MDA round, the social mobilization and distribution of door-to-door MDA contributed to 53% of overall resources employed, with personnel and logistics being the main cost drivers. The ICER improved over time as a result of decreasing costs and improved effectiveness. The overall ICER was $987 (CI95% 968-1,006) per DALY averted, which is below the standard cost-effectiveness (CE) threshold of $1,404/DALY averted, three times the gross domestic product (GDP) per capita of Mozambique, but above the threshold of interventions considered highly cost-effective (one time the GDP per capita or $468/DALY averted) and above the recently suggested thresholds based on the health opportunity cost ($537 purchasing power parity/ DALY averted). A significantly lower ICER was obtained in the implementation scenario from a governmental perspective ($441/DALY averted).

conclusionDespite the initial high costs and volume of resources associated with its implementation, MDA in combination with other existing malaria control interventions, can be a cost-effective strategy to drastically reduce transmission in areas of low to moderate transmission in sub-Saharan Africa. However, further studies are needed to understand the capacity of the health system and financial affordability to scale up such strategies at regional or national level.

Indexed as

Cost-Benefit AnalysisHumansMalariaMass Drug AdministrationMozambique

Identifiers

PMID32628741
PMCPMC7337313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.